Research programme: factor Xa inhibitor - Sanofi-Aventis

Drug Profile

Research programme: factor Xa inhibitor - Sanofi-Aventis

Alternative Names: SAR 377142

Latest Information Update: 18 Mar 2009

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Thromboembolism

Most Recent Events

  • 18 Mar 2009 No development reported - Preclinical for Thromboembolism in Europe (PO)
  • 25 May 2006 Preclinical trials in Thromboembolism in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top